FREMONT, Calif., Feb. 2, 2011 /PRNewswire/ -- WaferGen Biosystems, Inc. (OTC Bulletin Board: WGBS), a leading developer of state-of-the-art genomic analysis systems, today announced that it will present an overview of the company at the 13th annual BIO CEO and Investor Conference in New York City at the Waldorf Astoria Hotel, Tuesday, February 15, 2011 at 11:30 a.m. Eastern time. The presentation will be webcast live and archived for 90 days and may be accessed at www.wafergen.com.
The BIO CEO and Investor Conference is an international biotechnology investor conference featuring established and emerging public companies. For additional information, see http://www.bio.org/bioceo/.
WaferGen Biosystems, Inc. is a leader in the development, manufacture and sale of state-of-the-art systems for genomic analysis for the life science and pharmaceutical industries. The company currently offers the breakthrough SmartChip Real-Time PCR system, the next-generation Real-Time PCR system for discovery and validation of biomarkers, or gene expression patterns, on a single platform. The company believes that the SmartChip system is ideal for researchers seeking to confirm discoveries made with the growing use of next-generation sequencing. In addition, the high throughput capabilities of the SmartChip system enable scientists to extend their research across large panels of genes, and hundreds of samples, at a very reasonable cost.
In addition, the company offers an innovative fee-based service for gene-expression profiling using the SmartChip system. For additional information, please see http://www.wafergen.com.
SOURCE WaferGen Biosystems, Inc.